CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年8月31日～2025年9月6日の間に収集した論文情報を追加しました。

  1. Stacking the Risks: Fatal Consequences of Anabolic Steroid Misuse and Stacked Substance Use in FAERS Data.

  AAS乱用は多剤スタックで重篤化、若年層リスク高

  対象DB：FAERS,KAERS

  2. Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).

  ラロニダーゼAE、眼・中枢系含め長期監視必要

  対象DB：FAERS

  3. Aioli: Standardising Drugs in the FDA Adverse Event Reporting System (FAERS) to RxNorm and Anatomical Therapeutic Chemical (ATC) Codes.

  FAERS薬剤標準化Aioli高精度化示す

  対象DB：FAERS

  4. Pharmacovigilance study of ramucirumab: A safety analysis based on the FDA adverse event reporting system.

  ラムシルマブ実臨床で新規AE示唆

  対象DB：FAERS

  5. Characterizing the Real-World Risks of Kidney Injuries Associated with Chimeric Antigen Receptor T Cell Therapies-Evidence and Safety.

  CAR-T腎毒性なし、AKIはCRS管理重要

  対象DB：FAERS

  6. Association of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis.

  抗VEGF薬でIOI差異大、薬剤別に特徴的リスクあり

  対象DB：FAERS

  7. Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia.

  RSVワクチン3種は有効で安全性良好、長期検証中

  対象DB：FAERS,VAERS

  8. Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database.

  FAERSでペキシダルチニブ新規有害事象示唆

  対象DB：FAERS

  9. One Man's Meat Is Another Man's Poison: High Incidence of Severe Cutaneous Drug Reactions Induced by Enfortumab Vedotin.

  エンホルツマブ ベドチンで重篤皮膚AE多発

  対象DB：FAERS

  10. Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system.

  ズラノロンのFAERS解析：中枢神経系AE中心で早期発現

  対象DB：FAERS

  11. Seasonality and Trends in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Before and During the COVID-19 Pandemic: A Pharmacovigilance Study.

  FAERS解析でSJS/TENに季節性なし

  対象DB：FAERS

  12. Adverse drug events associated with sodium zirconium cyclosilicate: A real-world pharmacovigilance study based on the FAERS database.

  SZCのFAERS解析で早期AEシグナル検出

  対象DB：FAERS

  13. Systematic analysis and mechanistic investigation of cardiac adverse events associated with antibody-drug conjugates using FAERS database.

  ADCの心毒性リスクをFAERSで解析

  対象DB：FAERS

  14. Comprehensive safety assessment of ribociclib: A real-world analysis using the FDA Adverse Event Reporting System (FAERS) database.

  リボシクリブのFAERS安全性シグナル解析

  対象DB：FAERS

  15. A comprehensive study on drug-related Raynaud's phenomenon based on the FDA adverse event reporting system.

  薬剤誘発レイノー現象をFAERSで体系評価

  対象DB：FAERS

  16. Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.

  トリプトレリンで予期せぬ行動・認知症シグナル検出

  対象DB：FAERS

  17. The Adverse Event of Interstitial Lung Disease in Patients Treated with Antibody-Drug Conjugates.

  ADC関連間質性肺疾患の実態解析

  対象DB：FAERS

  18. Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 - 2024).

  ボクロスポリンで腎機能低下等確認

  対象DB：FAERS

  19. A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System(FAERS) Event for Belatacept.

  ベラタセプトで新規有害事象シグナル検出

  対象DB：FAERS

  20. Multifaceted safety concerns of glibenclamide in managing type 2 diabetes: Evidence from real-world adverse event analysis.

  グリベンクラミドで低血糖強シグナル確認

  対象DB：FAERS

  21. Analysis of differences in dupilumab-associated adverse drug event signals between children and adults based on the FAERS database.

  デュピルマブ有害事象は年齢で相違大

  対象DB：FAERS

  22. The post-marketing safety of Esketamine among older adults(>/= 65): an real-world pharmacovigilance study.

  エスケタミンで高齢者に重い精神系有害事象増加

  対象DB：FAERS

  23. Seasonal Variation in Diuretic-Induced Dehydration Using Spontaneous Reports of Adverse Events.

  利尿薬誘発脱水は冬夏に多く水分指導重要

  対象DB：JADER

  24. Tyrosine Kinase Inhibitors and Interstitial Lung Disease: A Disproportionality Analysis Using the European Post-marketing EudraVigilance Database.

  TKIで薬剤性間質性肺疾患の信号強く注意喚起

  対象DB：EudraVigilance

  25. Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.

  GLP-1受容体作動薬でウェルニッケ脳症リスク示唆

  対象DB：VigiBase

  26. Exploring the Reliability of Detecting Drug-Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems.

  妊娠期の薬剤相互作用検出は不確実で検証要請

  対象DB：VigiBase

  27. Virtual Hepatic and Plasma Exposures of Voriconazole Administered to Cytochrome P450 2C19 Poor Metabolizers Predicted by Simplified and Full Pharmacokinetic Modeling Systems: Possible Causal Factor for Hepatic Disorders Seen in a Japanese Database.

  CYP2C19低代謝者でVRC肝曝露高く減量推奨

  対象DB：JADER

  28. Validity of diagnoses, procedures, and birth records in a Japanese administrative claims database for pediatric patients.

  日本の小児診療データの信頼性評価:診断・手技の一致性分析結果

  対象DB：DPC

  29. Real world treatment patterns and unmet needs of migraine preventive treatments in Japan: JMDC claims analysis.

  日本における片頭痛予防薬の治療状況と課題:持続率と切り替え分析

  対象DB：JMDC

  30. Trends in prescription opioid use in Europe: A DARWIN EU((R)) multinational cohort study including seven European countries.

  欧州におけるオピオイド使用の動向と課題:多国籍コホート研究結果

  対象DB：CPRD

  31. The impact of learning disabilities on control, management, and outcomes of type 2 diabetes mellitus in the UK: an observational cohort study using the Clinical Practice Research Datalink.

  学習障害を持つT2DM患者の管理と予後:UKでのコホート研究結果

  対象DB：CPRD

  32. Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study.

  COVID後遺症予防におけるメトホルミンの可能性:肥満患者対象の検討

  対象DB：CPRD

  33. Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.

  NVAFとPAD患者におけるリバーロキサバンとアピキサバンの安全性比較

  対象DB：CPRD

  34. Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians.

  膵管腺癌の中期リスク因子:早期発見モデルの構築可能性

  対象DB：THIN

  35. Dietary Habits and Osteoporotic Fracture Risk: Retrospective Cohort Study Using Large-Scale Claims Data.

  食習慣と骨粗鬆症性骨折リスク:朝食欠食と夜遅い夕食の影響

  対象DB：DeSC

  36. Lean body mass index and the risk of diabetes onset: A nationwide epidemiological cohort study.

  薬剤性歯肉疾患の新規リスク因子:FAERS分析と臨床への示唆

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み